ReviewTranslational andrology and urology2015
Advances in the treatment of testicular cancer.
Review in Translational andrology and urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Health-Related Quality of Life Following Treatment for Testicular Cancer: A Qualitative Systematic Review.American journal of men's healthPooled it
- Cisplatin-incorporating gelatin-coated gadolinium oxide nanoparticles for cancer theranostics.iScience · 2026Article
- Role of Retroperitoneal Lymph Node Dissection in Management of Seminomatous Germ Cell Tumor: A Narrative Review.Indian journal of surgical oncology · 2025Review
- Treatment de-escalation for stage II seminoma.Nature reviews. Urology · 2023Review
- Oleuropein Counteracts Both the Proliferation and Migration of Intra- and Extragonadal Seminoma Cells.Nutrients · 2022Article
- Testicular cancer metastasis to the soft tissue: A case report and review of the literature.Radiology case reports · 2021Article
- The Good, the Bad and the Ugly of Testicular Immune Regulation: A Delicate Balance Between Immune Function and Immune Privilege.Advances in experimental medicine and biology · 2021Review
- Treatment of germ cell testicular cancer.Acta clinica Croatica · 2020Review
- Multimodality Radiological Pictorial Review of Testicular Carcinoma: From Initial Staging to Restaging.Research and reports in urology · 2020Review
- DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Molecular diagnosis & therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germ cell tumors (GCT) are relatively uncommon, accounting for only 1% of male malignancies in the United States. It has become an important oncological disease for several reasons. It is the most common malignancy in young men 15-35 years old. GCTs are among a unique numbers of neoplasms where biochemical markers play a critical role. Finally, it is a model of curable cancer. In this review we discuss cancer epidemiology, genetics, and therapeutic principles. Recent advances in the management of stage I GCT and controversies in the management of post chemotherapy residual mass are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.